Digital Therapeutics (DTx): How Are These Solutions Evolving in Spain in 2025?

Digital Therapeutics (DTx) continue to experience exponential growth, emerging as innovative solutions that are transforming how we prevent, manage, and treat a wide range of diseases and conditions. Over the past three years, investment in DTx companies has reached an estimated EUR 1 billion — a 92% increase compared with the cumulative total of the previous six years. Looking ahead, the market is expected to keep expanding, reaching USD 56.76 billion in funding by 2034 and positioning DTx as the fastest growing category in Digital Health.

Across Europe, several countries are consolidating the adoption of DTx solutions, including Germany, France, and the United Kingdom. Germany, the most advanced market in terms of implementation, published an updated DiGA Report in 2024 showing an 80% increase in activations of Digital Health applications over the last 15 months and nearly 1 million digital prescriptions issued since the launch of the programme.

This sustained momentum is encouraging the adoption of DTx in additional European markets – among them, Spain. The integration of Digital Therapeutics into clinical practice in the country is becoming increasingly viable, supported by developments such as:

- The creation of the DTx Consortium and the publication of its White Paper (updated September 2025), which analyses the global landscape of Digital Therapeutics, their impact, and a roadmap for their adoption in Spain.
- Growing consensus and collaboration among key healthcare stakeholders — industry, technology companies, insurers, startups, and patient associations — under the umbrella of the DTx Consortium. This reflects both the increasing interest in DTx and the value they bring to the health system.
- The commitment of the Spanish National Health System (SNS) to digitalisation, driven by the Digital Strategy for 2026 and its progress report, which highlights the potential of Digital Health solutions across the ecosystem. In addition, the Digital Transformation Plan for Primary Care, already underway in at least 14 regions, is accelerating progress in telemonitoring, connected devices integration, and automation.
- Regional initiatives to develop specific assessment frameworks for Digital Health technologies, such as the “Healthcare Technology Assessment Framework: adaptation for the evaluation of digital health technologies”, published by the Catalan Agency for Health Quality and Assessment (AQuAS) in 2023 and updated in November 2024.
- The public consultation on a new Royal Decree to regulate the assessment of health technologies. As part of this process, the DTx Consortium has highlighted the need for specific regulatory considerations for Digital Therapeutics, taking into account their particularities.

Together, these developments demonstrate Spain’s strong commitment to advancing Digital Health and reinforce the growing role of Digital Therapeutics within the national healthcare landscape. The active engagement of key healthcare stakeholders, combined with public-sector momentum in digitalisation, is laying the foundation for the effective integration of DTx into the Spanish health system, contributing to more personalised, efficient, and sustainable care.